In addition to CAD and dyslipidemia, genetic variants in TOMM40 have been investigated in other contexts, having been associated with reduced BMI (Guo et al., 2013), lower levels of high-sensitivity C-reactive protein (hs-CRP) (Ellis et al., 2014; Christiansen et al., 2017a), healthy aging and longevity (Deelen et al., 2011; 2014; Chen et al., 2022; Torres et al., 2022) and increased risk of Alzheimer’s disease (Denny et al., 2013; Davies et al., 2015). Here, TOMM40 is linked to metabolic syndrome.